



(Original release in Japanese)

A2 Healthcare Corporation  
Vitalive Inc.

## A2 Healthcare and Vitalive Announce to Streamline Survival Follow-Up and Accelerate Digital Transformation in Oncology Clinical Trials

A2 Healthcare Corporation (Headquarter: Bunkyo-ku, Tokyo; President and CEO: Hitoshi Kamiya; hereinafter "A2") and Vitalive Inc. (Head Office: Minato-ku, Tokyo; CEO: Makoto Inoue; hereinafter "Vitalive") have entered into a partnership to promote the use of "VitaliveOS," a system developed by Vitalive, with the aim of improving the efficiency of survival follow-up in oncology clinical trials.

The practice of conducting survival follow-up in oncology trials, both in Japan and overseas, is predominantly carried out via telephone, which imposes significant psychological and financial burdens on patients, clinical research nurses(CRNs), and Clinical Research Associates (CRAs). The innovative use of SMS (Short Message Service) for survival follow-up, as proposed by Vitalive, helps reduce this burden and contributes to greater efficiency in clinical trials. Through this collaboration, A2 will utilize its vast domestic and global network to promote the adoption of VitaliveOS, thereby fostering efficiency in clinical trial operations. In recent years, the rising human and economic costs, coupled with the increasing complexity of large-scale trials have become major challenges. On the medical institution side, unresolved burdens such as scheduling, phone-based follow-up, data entry, and the emotional toll of interviewing patients remain unresolved. Meanwhile, the trial sponsors side, securing CRA resources for survival follow-up monitoring and the associated increase in clinical trial costs are persistent issues.

VitaliveOS is a platform that digitalizes survival follow-up, allowing CRNs to distribute surveys via SMS through the system without making phone calls. The responses are automatically collected and can be used as source data, significantly reducing the workload for CRNs and CRAs.

Through collaboration between A2 and Vitalive, this initiative not only streamlines the development process by reducing site visits for monitoring but also contributes to a sustainable future by reducing CO2 emissions.

Our goal is to fulfill the social mission of delivering new medical treatments to as many patients as possible, as soon as possible.



**【About A2 Healthcare Corporation】**

A leading CRO with approximately 1,300 employees across Tokyo, Osaka, Taiwan, and Boston, A2 Healthcare has been involved in numerous domestic and international drug development projects. In addition to its expertise in lifestyle-related diseases, the company specializes in oncology, CNS, respiratory, vaccines, and regenerative medicine. A2 Healthcare promotes clinical trial efficiency through advanced solutions such as RBM, eSource Data, eSubmission, and Decentralized Clinical Trials. It plays a central role in the healthcare business of the ITOCHU Corporation Group.

Website: <http://www.a2healthcare.com>

**【About Vitalive Inc.】**

Founded in July 2024 in Minato-ku, Tokyo, Vitalive is a startup focused on solving issues in clinical trials. With the mission of "bringing happiness to everyone involved in clinical trials," the company launched "VitaliveOS" in February 2025 — a system that automates survival follow-up. Vitalive has obtained ISO 27001 (Information Security Management System) certification and is actively developing reliable systems in collaboration with academia and pharmaceutical companies.

Website: <https://www.vitalive.co.jp>

**【Please contact below for any question】**

A2 Healthcare Corporation  
Business Development Division  
Frontier Business Department  
E-mail : [marke@a2healthcare.com](mailto:marke@a2healthcare.com)

Vitalive Inc.  
E-mail: [contact@vitalive.co.jp](mailto:contact@vitalive.co.jp)